News About: Pharm. Affairs
‘Fycompa’ turned in the registration of the health insurance benefit, giving an advance notice as a new mechanism of epilepsy treatment
A prescription option for a new mechanism of epilepsy treatment is going to be added.
According to the industry concerned on the 30th, Eisai has turned in a registration application of the health insurance benefit fo...
Doctors from applicant hospitals are not allowed to participate in the deliberation committee for the super expensive drug, Soliris
Restriction is now placed for medical doctors the related hospital which applied for the insurance benefit of the paroxysmal nocturnal hemoglobinuria(PNH) treatment, Soliris Inj(eculizumab), not to be involved with vo...
The KRW 4 trillion hair loss market has leaked into shade while the government is not approving the DPCP treatment
While the government indicated the most effective treatment for severe hair loss patients, ‘DPCP(Diphenylcyclopropenone)’ as illegal, there is no regulation to control wrong folk remedies or beliefs; thus, a criticism...
The ‘monopolistic’ brain tumor treatment ‘Temodal’ will face 3-way competition against domestic pharmaceutical products
As a domestic pharmaceutical company entered the MSD’s brain tumor treatment ‘Temodal(temozolomide)’ market, the 3-way competition is expected to be formed.
Temodal was expired in patent on December 2011, but has tak...
Pharmacists pay attention to the next pharmacy claim SW which will replace PM2000
“We will provide a new program with the highest security system which will make no damage to pharmacies using PM2000.”
This is a part of the statement of Chan-hui Jo, the president of the Korean Pharmaceutical Associ...
Novo and Sanofi expects to make fierce competition over the next term’s insulin
The strong of insulin are going to compete in its market for the next term. They have not been unveiled, but will be launched within this year to preoccupy the market.
According to the industry concerned on the 27th,...
A domestic biosimilar taking an unstoppable run in the global market
The Celltrion’s rheumatoid arthritis treatment, ‘Remsima,’ has continued to accelerate in the global market. The number of exports from the early year to June has already exceeded the one of the last whole year.
Rems...
The 2nd domestic DPP-4 inhibitor attracted attention with high expectation of global commercialization
The DPP-4(dipepitdyl peptidase-4) diabetes new drug developed by Dong-A ST for the second time as a domestic company, Evogliptin, is expected to become a role model of the global commercialization.
This is because th...
24 people from Korea Pharmaceutical Information Center and IMS were suspected for leaking personal information
On suspicion of illegal collection and sales of patient treatment and prescription information, 24 people from institutions, such as the Korea Pharmaceutical Information Center and IMB Health Korea, were prosecuted.
...
What are so ‘innovative’ about ‘NOAC’ applauded by physicians?
Foreign and domestic guidelines, recently, have aggressively recommended NOAC(New-Oral Anti-Coagulant) as an anticoagulant to prevent stoke and systemic embolism of atrial fibrillation patients.
Thus, NOAC has been a...
